Ensol Biosciences Inc.
AI-driven biopharma developing peptide drugs for unmet medical needs.
140610 | KO
Overview
Corporate Details
- ISIN(s):
- KR7140610007
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 유성구 테크노10로 51(탑립동), 대전광역시
- Website:
- https://www.ensolbio.co.kr/eng/
- Sector:
- Manufacturing
Description
Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-12-09 00:00 |
전환가액의조정(제3회차 CB)
|
Korean | 9.7 KB | ||
| 2022-12-02 00:00 |
조회공시요구(풍문또는보도)에대한답변(미확정)
|
Korean | 5.9 KB | ||
| 2022-11-04 00:00 |
조회공시요구(풍문또는보도)에대한답변(미확정)
|
Korean | 5.7 KB | ||
| 2022-10-26 00:00 |
기업설명회(IR)개최결과
|
Korean | 6.6 KB | ||
| 2022-10-12 00:00 |
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2022-10-06 00:00 |
조회공시요구(풍문또는보도)에대한답변(미확정)
|
Korean | 5.5 KB | ||
| 2022-10-05 00:00 |
조회공시요구(풍문또는보도)(코스닥시장 이전상장 추진설)
|
Korean | 3.4 KB | ||
| 2022-09-30 00:00 |
기타주요경영사항(자율공시)(퇴행성 디스크 질환 치료제(P2K) 마일스톤 기술료 수령)
|
Korean | 4.6 KB | ||
| 2022-09-23 00:00 |
기타주요경영사항(자율공시)(기술평가 결과)
|
Korean | 6.3 KB | ||
| 2022-09-15 00:00 |
임상시험단계진입ㆍ종료(자율공시)(삼중음성유방암치료제 카리스1000(C1K) 제1상 임상시험 계획 승인)
|
Korean | 7.5 KB | ||
| 2022-08-16 00:00 |
전환가액의조정(제1회차 CB)
|
Korean | 9.6 KB | ||
| 2022-07-15 00:00 |
기타주요경영사항(자율공시)(전환우선주 전환가액 조정)
|
Korean | 7.5 KB | ||
| 2022-06-10 00:00 |
기타주요경영사항(자율공시)(기술성평가 신청)
|
Korean | 3.8 KB | ||
| 2022-06-09 00:00 |
증권발행결과(자율공시)(제3회차 CB)
|
Korean | 5.4 KB | ||
| 2022-06-07 00:00 |
기업설명회(IR)개최결과
|
Korean | 6.7 KB |
Automate Your Workflow. Get a real-time feed of all Ensol Biosciences Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ensol Biosciences Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ensol Biosciences Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
